a therapeutically effective amount of suprofen for topical treatment of inflammation of the eye, and pharmaceutically acceptable salts thereof;

a xanthine derivative being present in an amount between the amount of derivative soluble in the water of said composition and 0.05% by weight/volume of said composition which is effective to reduce the discomfort associated with suprofen upon
topical application of said composition, said xanthine derivative being selected from the group consisting of theophylline, caffeine, theobromine and mixtures thereof;

3. An aqueous, nonirritating, nonsteroidal ophthalmic composition as recited in claim 2 wherein said suprofen comprises between about 0.5 to about 3.0 percent by weight/volume of said ophthalmic composition.

4. A method for reducing the stinging and discomfort associated with the topical application to the eye of an aqueous solution of a therapeutically effective amount of anti-inflammatory agent for topical treatment of inflammation of the eye,
said agent selected from the group consisting of mefenamic acid, flufenamic acid, clonixin, flufenisal, 4-(t-butyl)benzeneacetic acid, ibufenac, ibuprofen, alclofenac, feneprofen, naproxen, indomethacin, tolmetin, flurbiprofen, ketoprofen, namoxyrate,
suprofen, pharmaceutically acceptable salts of the foregoing acids and mixtures thereof, said method comprising adding to said aqueous solution an xanthine derivative in an amount between the amount of derivative soluble in the water of said composition
and 0.05% by weight/volume of said composition which is effective to reduce the discomfort associated with said anti-inflammatory agent upon said topical application, said xanthine derivative having the formula ##STR2## where each of R.sub.1, R.sub.2 and
R.sub.3 is selected from hydrogen, methyl and ethyl, and at least two of R.sub.1, R.sub.2 and R.sub.3 are selected from methyl and ethyl, and mixtures thereof forming a nonirritating ophthalmic composition.

5. A method as recited in claim 4 wherein said xanthine derivative is selected from the group consisting of theophylline, caffeine, theobromine and mixtures thereof.

6. A method as recited in claim 5 wherein said anti-inflammatory agent is suprofen and said xanthine derivative is caffeine.

7. A method as recited in claim 6 wherein said suprofen comprises between about 0.5 to about 3.0 percent by weight/volume of said ophthalmic composition.

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.